Вы искали: leveraminotransferaser (Датский - Английский)

leveraminotransferaser
liver aminotransferases

forhøjede leveraminotransferaser
hepatic transaminase elevations

forhøjelse af leveraminotransferaser
hepatic transaminase elevations

forhøjede leveraminotransferaser i blodet
increased liver transaminases in your blood

unormal leverfunktion, forhøjede leveraminotransferaser.
hepatic function abnormal, transaminases increased.

der blev observeret forhøjede leveraminotransferaser i placebokontrollerede studier.
in placebo-controlled studies, elevations of hepatic transaminases were observed.

forhøjede leveraminotransferaser, vægtøgning, øget total- bilirubin*
hepatic transaminases increased, weight increased, total bilirubin increased

forbigående, asymptomatisk forhøjede leveraminotransferaser (alat, asat), særlig
transient, asymptomatic elevations of hepatic aminotransferases

· basislinieværdier for leveraminotransferaser, dvs. aspartataminotransferaser (asat) og/eller
· baseline values of liver aminotransferases, i. e., aspartate aminotransferases (ast) and/or

klinisk status, herunder niveauet af leveraminotransferaser og bilirubin, bør overvåges.
clinical status including liver aminotransferases and bilirubin should be monitored.

den kliniske status, herunder niveauet af leveraminotransferaser og bilirubin, bør overvåges.
clinical status including liver aminotransferases and bilirubin should be monitored.

patienter med baselineværdier for leveraminotransferaser (asat og/eller alat) 3 x uln.
patients with baseline values of hepatic aminotransferases (ast and/or alt) 3x uln.

forbigående, asymptomatiske forhøjelser af leveraminotransferaser alat og asat er almindeligt forekommende, især initialt i behandlingen.
transient, asymptomatic elevations of hepatic aminotransferases, alt, ast have been seen commonly, especially in early treatment.

bosentan har været forbundet med dosisrelaterede forøgelser af leveraminotransferaser, dvs. aspartat - og alaninaminotransferaser.
bosentan has been associated with dose-related elevations in liver aminotransferases, i.e., aspartate and alanine aminotransferases.

tracleer må ikke bruges samtidigt med glibenclamid på grund af en øget risiko for forhøjede leveraminotransferaser (se pkt.
tracleer should not be used concomitantly with glibenclamide, due to an increased risk of elevated liver aminotransferases (see section 4.5).

i tilfælde af en signifikant forhøjelse af leveraminotransferaser bør dosis af esbriet justeres, eller behandlingen afbrydes efter nedenstående retningslinjer.
in the event of significant elevation of liver aminotransferases the dose of esbriet should be adjusted or treatment discontinued according to the guidelines listed below.

den øgede hyppighed af forhøjede leveraminotransferaser hos patienter behandlet med tecfidera i forhold til placebo sås primært i de første 6 måneder af behandlingen.
the increased incidence of elevations of hepatic transaminases in patients treated with tecfidera relative to placebo was primarily seen during the first 6 months of treatment.

i det kliniske program forekom dosisafhængige stigninger i leveraminotransferaser generelt inden for de første 26 uger af behandlingen, i reglen udviklet gradvist og hovedsageligt asymptomatisk.
in the clinical programme, dose-dependent elevations in liver aminotransferases generally occurred within the first 26 weeks of treatment, usually developed gradually, and were mainly asymptomatic.

under administration af simeprevir sammen med peginterferon alfa og ribavirin var stigningerne i direkte og indirekte bilirubin generelt ikke forbundet med stigninger i leveraminotransferaser og blev normaliseret efter afslutning af behandlingen.
during administration of simeprevir with peginterferon alfa and ribavirin, the elevations in direct and indirect bilirubin were generally not associated with elevations in liver transaminases and normalised after end of treatment.

stigninger i leveraminotransferaser (asat, alat) er blevet forbundet med pah og med endothelinreceptorantagonister (era’er).
elevations of liver aminotransferases (ast, alt) have been associated with pah and with endothelin receptor antagonists (eras).